Clutch has been in use since shortly after its FDA 510(k) clearance in 2017 and with this expanded commercial release, Spinal Elements again sets the new standard with a unique and clinically relevant feature: The Clutch interspinous process device’s proprietary spring-activated mechanism is designed to maintain active compression against the spinous processes to resist loosening and migration. Additionally, the device’s bone opposing surfaces are enhanced with clinically proven Ti-Bond technology, designed to provide immediate stability and long-term fixation.
“I have found interspinous process devices to be a very useful surgical option in my practice. Clutch has an ideal anatomic design that lets me confidently place the device in a more anterior position, fixating securely into the best quality bone,” said Dr. Burak Ozgur, a nationally recognized neurosurgeon in Newport Beach, Calif. Jason Blain, president and CEO of Spinal Elements added, “Creating procedural solutions for improved patient outcomes is a critical requirement for every system we design and market. Clutch meets this need with what we believe to be a best-in-class design. I am excited for how this addition complements and expands our product portfolio.”